Download PDF
Horm Metab Res 2020; 52(02): 89-94
DOI: 10.1055/a-1084-5441
Endocrine Care
© Georg Thieme Verlag KG Stuttgart · New York

Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study

Aafia Rashid
1   Department of Endocrinology, Sheri-Kashmir Institute of Medical Sciences, Srinagar, India
,
Mohd Ashraf Ganie
1   Department of Endocrinology, Sheri-Kashmir Institute of Medical Sciences, Srinagar, India
,
Imtiyaz Ahmad Wani
1   Department of Endocrinology, Sheri-Kashmir Institute of Medical Sciences, Srinagar, India
,
Gulzar Ahmad Bhat
1   Department of Endocrinology, Sheri-Kashmir Institute of Medical Sciences, Srinagar, India
,
Feroz Shaheen
2   Department of Radio-Diagnosis, Sheri-Kashmir Institute of Medical Sciences, Srinagar, India
,
Ishfaq Ahmed Wani
1   Department of Endocrinology, Sheri-Kashmir Institute of Medical Sciences, Srinagar, India
,
Mukesh Shrivastava
3   Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India
,
Zaffar Amin Shah
4   Department of Immunology & Molecular Medicine, Sheri-Kashmir Institute of Medical Sciences, Srinagar, India
› Author Affiliations Funding details This research was performed independently of any funding as part of institutional activities of the investigators and researchers.
Further Information

Publication History

received 18 September 2019

accepted 11 December 2019

Publication Date:
13 February 2020 (online)

Also available at
    Permissions and Reprints

Abstract

Women with PCOS are linked to insulin resistance, inflammation, and vitamin D (VD) deficiency. The study endeavors to comprehend the differential impact of insulin sensitizers vs. anti-androgen on serum leptin levels among women with PCOS rendered vitamin D replete with high VD oral supplement. This was open-labeled randomized study that screened 180 eligible women presenting to Endocrine clinic with oligomenorrhea or features of hyperandrogenism. Ninety-nine women who furnished written informed consent and fulfilled the Rotterdam 2003 criteria for diagnosis of PCOS were randomized into 3 drug treatment arms to receive either spironolactone (50 mg/d; n=30), metformin (1000 mg/d; n=30) or pioglitazone (30 mg/d; n=30). These women were also administered oral VD (4000 IU/day) in addition to the allocated drug for a period of 6 months. Detailed history, clinical examination, and laboratory evaluation was carried out at baseline and 6 months after intervention. Number of menstrual cycles/year increased while as Ferriman–Gallwey score, blood glucose, HOMA-IR, and plasma insulin levels significantly decreased in all the three arms with better outcomes in spironolactone and pioglitazone arms (p<0.05). Similarly, serum leptin levels superiorly improved in spironolactone and pioglitazone group. Pioglitazone group showed better efficacy in lowering serum total testosterone (p<0.05). Co-supplementation of high dosage VD with spironolactone or pioglitazone are more effective in reducing plasma leptin levels than metformin, and thus might prove to be better therapeutic strategies for women with PCOS.

Key words

polycystic ovary syndrome - hyperandrogenism - insulin resistance - inflammation serum leptin
 

  • References

  • 1 Carmina E, Lobo RA. Polycystic Ovary Syndrome (PCOS): Arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897-1899
    CrossrefPubMedGoogle Scholar
  • 2 Dumesic DA, Akopians AL, Madrigal VK. et al. Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab 2016; 101: 4178-4188
    CrossrefPubMedGoogle Scholar
  • 3 Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 33S-39S
    PubMedGoogle Scholar
  • 4 Ollila M-ME, West S, Keinänen-Kiukaanniemi S. et al. Overweight and obese but not normal weight women with PCOS are at increased risk of Type 2 diabetes mellitus—a prospective, population-based cohort study. Hum Reprod 2017; 32: 423-431
    CrossrefPubMedGoogle Scholar
  • 5 Lin T-C, Yen J-M, Gong K-B. et al. Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst the Taiwanese population- not correlated with insulin receptor substrate-1 Gly972Arg/Ala513Pro polymorphism. BMC Med Genet 2006; 7: 36
    PubMedGoogle Scholar
  • 6 Macut D, Tziomalos K, Božić-Antić I. et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod 2016; 31: 1347-1353
    CrossrefPubMedGoogle Scholar
  • 7 Nehir Aytan A, Bastu E, Demiral I. et al. Relationship between hyperandrogenism, obesity, inflammation and polycystic ovary syndrome. Gynecol Endocrinol 2016; 32: 709-713
    CrossrefPubMedGoogle Scholar
  • 8 Peng Z, Sun Y, Lv X. et al. Interleukin-6 levels in women with polycystic ovary syndrome: a systematic review and meta-analysis. PLoS One 2016; 11: e0148531
    CrossrefPubMedGoogle Scholar
  • 9 Sathyapalan T, Javed Z, Kilpatrick ES. et al. Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2017; 86: 384-387
    CrossrefPubMedGoogle Scholar
  • 10 Adams J, Liu Z, Ren YA. et al. Enhanced inflammatory transcriptome in the granulosa cells of women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2016; 101: 3459-3468
    CrossrefPubMedGoogle Scholar
  • 11 Koleva DI, Orbetzova MM, Nikolova JG. et al. Adipokines and soluble cell adhesion molecules in insulin resistant and non-insulin resistant women with polycystic ovary syndrome. Arch Physiol Biochem 2016; 122: 223-227
    CrossrefPubMedGoogle Scholar
  • 12 Zheng S-H, Li X-L. Visceral adiposity index as a predictor of clinical severity and therapeutic outcome of PCOS. Gynecol Endocrinol 2016; 32: 177-183
    CrossrefPubMedGoogle Scholar
  • 13 Yannakoulia M, Yiannakouris N, Blüher S. et al. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003; 88: 1730-1736
    CrossrefPubMedGoogle Scholar
  • 14 Glintborg D, Andersen M, Hagen C. et al. Evaluation of metabolic risk markers in polycystic ovary syndrome (PCOS). Adiponectin, ghrelin, leptin and body composition in hirsute PCOS patients and controls. Eur J Endocrinol 2006; 155: 337-345
    CrossrefPubMedGoogle Scholar
  • 15 Joham AE, Teede HJ, Cassar S. et al. Vitamin D in polycystic ovary syndrome: Relationship to obesity and insulin resistance. Mol Nutr Food Res 2016; 60: 110-118
    CrossrefPubMedGoogle Scholar
  • 16 Mishra S, Das AK, Das S. Hypovitaminosis D and Associated Cardiometabolic Risk in Women with PCOS. J Clin Diagonstic Res 2016; 10: BC01-4
    PubMedGoogle Scholar
  • 17 Dinca M, Serban M-C, Sahebkar A. et al. Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2016; 107: 360-371
    CrossrefPubMedGoogle Scholar
  • 18 Figurová J, Dravecká I, Petríková J. et al. The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. Horm Mol Biol Clin Investig 2017; 29: 85-91
    PubMedGoogle Scholar
  • 19 Tang T, Lord JM, Norman RJ et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012; CD003053
    PubMed
  • 20 Ganie MA, Khurana ML, Nisar S. et al. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with Polycystic Ovary Syndrome (PCOS): A six-month, open-label randomized study. J Clin Endocrinol Metab 2013; 98: 3599-3607
    CrossrefPubMedGoogle Scholar
  • 21 Ashraf Ganie M, Khurana ML, Eunice M. et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: An open-labeled study. J Clin Endocrinol Metab 2004; 89: 2756-2762
    CrossrefPubMedGoogle Scholar
  • 22 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
    CrossrefPubMedGoogle Scholar
  • 23 Geller DH, Pacaud D, Gordon CM. et al. State of the art review: Emerging therapies: The use of insulin sensitizers in the treatment of adolescents with Polycystic Ovary Syndrome (PCOS). Int J Pediatr Endocrinol 2011; 2011: 9
    CrossrefPubMedGoogle Scholar
  • 24 Kulshreshtha B, Gupta N, Ganie MA. et al. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome – a retrospective analysis. Gynecol Endocrinol 2012; 28: 823-826
    CrossrefPubMedGoogle Scholar
  • 25 Zulian E, Sartorato P, Benedini S. et al. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005; 28: 49-53
    CrossrefPubMedGoogle Scholar
  • 26 Bajuk Studen K, Šebeštjen M, Pfeifer M. et al. Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2011; 164: 389-395
    CrossrefPubMedGoogle Scholar
  • 27 Messinis IE, Messini CI, Anifandis G. et al. Polycystic ovaries and obesity. Best Pract Res Clin Obstet Gynaecol 2015; 29: 479-488
    CrossrefPubMedGoogle Scholar
  • 28 Fang F, Ni K, Cai Y. et al. Effect of vitamin D supplementation on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract 2017; 26: 53-60
    CrossrefPubMedGoogle Scholar
  • 29 Tan BK, Chen J, Hu J. et al. Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2013; 98: E1891-E1900
    CrossrefPubMedGoogle Scholar
  • 30 Karonova T, Belyaeva O, Jude EB. et al. Serum 25(OH)D and adipokines levels in people with abdominal obesity. J Steroid Biochem Mol Biol 2018; 175: 170-176
    CrossrefPubMedGoogle Scholar
  • 31 Kim JY, Tfayli H, Michaliszyn SF. et al. Distinguishing characteristics of metabolically healthy versus metabolically unhealthy obese adolescent girls with polycystic ovary syndrome. Fertil Steril 2016; 105: 1603-1611
    CrossrefPubMedGoogle Scholar
  • 32 Chen C-I, Hsu M-I, Lin S-H. et al. Adiponectin and leptin in overweight/obese and lean women with polycystic ovary syndrome. Gynecol Endocrinol 2015; 31: 264-268
    CrossrefPubMedGoogle Scholar
  • 33 Cohen B, Novick D, Rubinstein M. Modulation of insulin activities by leptin. Science 1996; 274: 1185-1188
    CrossrefPubMedGoogle Scholar
  • 34 Jacobs HS, Conway GS. Leptin, polycystic ovaries and polycystic ovary syndrome. Hum Reprod Update 5: 166-171
    PubMedGoogle Scholar
  • 35 Svendsen PF, Christiansen M, Hedley PL. et al. Adipose expression of adipocytokines in women with polycystic ovary syndrome. Fertil Steril 2012; 98: 235-241
    CrossrefPubMedGoogle Scholar
  • 36 Plati E, Kouskouni E, Malamitsi-Puchner A. et al. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation. Fertil Steril 2010; 94: 1451-1456
    CrossrefPubMedGoogle Scholar